Companies making headlines before the bell:» Read More
WASHINGTON— Standard& Poor's releases S&P/Case-Shiller index of home prices for May, 9 a.m.. WASHINGTON— The Conference Board releases the Consumer Confidence Index for July, 10 a.m.. WASHINGTON— House Energy and Commerce subcommittee hearing on EPA's proposed clean power plan and grid reliability challenges.
Baxter International Inc. fell$. 28 or. 4 percent, to $76.38. Bristol-Myers Squibb Co. rose$. 02 or percent, to $49.41. Hospira rose $1.03 or 2.0 percent, to $52.75.
NEW YORK— A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. Advanced Micro Devices Inc. fell. 9 percent to $3.73 with 14,586,800 shares traded. Bank of America Corp. fell. 8 percent to $15.47 with 20,278,100 shares traded.
Baxter International Inc. fell$. 10 or. 1 percent, to $76.55. Bristol-Myers Squibb Co. fell$. 21 or. 4 percent, to $49.18. Hospira rose $2.43 or 4.7 percent, to $54.15.
NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
Baxter International Inc. rose$. 16 or. 2 percent, to $77.00. Bristol-Myers Squibb Co. rose$. 14 or. 3 percent, to $49.46. Hospira rose $1.16 or 2.3 percent, to $51.82.
At least eight European law firms are pitching their services to major U.S. law firms and Wall Street banks, hoping that U.S. companies considering an inversion choose Ireland, Britain or the Netherlands for their new tax domicile, according to people with knowledge of the matter.
July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.
Baxter International Inc. rose$. 20 or. 3 percent, to $77.04. Bristol-Myers Squibb Co. rose$. 20 or. 4 percent, to $49.52. Hospira rose$. 74 or 1.5 percent, to $51.40.
Baxter International Inc. fell$. 13 or. 2 percent, to $76.71. Bristol-Myers Squibb Co. fell$. 16 or. 3 percent, to $49.16. Hospira rose$. 03 or. 1 percent, to $50.69.
July 24- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings beat forecasts.
NEW YORK— Bristol-Myers Squibb Co.' s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.
President Barack Obama’s push to deter U.S. firms from buying foreign companies for tax purposes will make several deals less attractive.
LOS ANGELES— Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers. "I don't care if it's legal," Obama declared.
U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range. The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.
Puma Biotechnology's experimental breast cancer drug met its main goal in a late-stage trial, but the options market is sensing something funky.
July 22- Puma Biotechnology Inc said its experimental breast cancer drug met its main goal in a late-stage trial. Shares of the company, which doesn't have any drug in the market, tripled to $176.94 in extended trading.
Baxter International Inc. rose$. 76 or 1.0 percent, to $76.87. Bristol-Myers Squibb Co. rose$. 20 or. 4 percent, to $49.12. Hospira rose$. 31 or. 6 percent, to $50.78.
Baxter International Inc. rose$. 93 or 1.2 percent, to $77.04. Bristol-Myers Squibb Co. rose$. 41 or. 8 percent, to $49.33. Hospira rose$. 27 or. 5 percent, to $50.74.
Democrats, searching for campaign issues before November's congressional elections, have jumped on inversions, and several of them have offered bills that would curb the deals.